{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:12:17Z","timestamp":1772795537156,"version":"3.50.1"},"reference-count":33,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Biological agents are being increasingly used in the UK for paediatric-onset inflammatory bowel disease (PIBD) despite limited evidence and safety concerns. We evaluated effectiveness and safety in the clinical setting, highlighting drug cost pressures, using our national Scottish PIBD biological registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Complete usage of the biological agents, infliximab (IFX) and adalimumab (ADA) for treatment of PIBD (in those aged &lt;18\u2005years) from 1 January 2000 to 30 September 2010 was collated from all treatments administered within the Scottish Paediatric Gastroenterology, Hepatology and Nutrition (PGHAN) national managed service network (all regional PGHAN centres and paediatric units within their associated district general hospitals).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>132 children had biological therapy; 24 required both agents; 114 had Crohn's disease (CD), 16 had ulcerative colitis (UC) and 2 had IBD Unclassified (IBDU). 127 children received IFX to induce remission; 61 entered remission, 49 had partial response and 17 had no response. 72 were given maintenance IFX\u00a0and 23 required dose escalation. 18 had infusion reactions and 27 had adverse events (infections\/other adverse events). 29 had ADA to induce remission (28 CD and 1 UC), 24 after IFX; 10 entered remission, 12 had partial response and 7 had no response. All had maintenance; 19 required dose escalation. 12 children overall required hospitalisation due to drug toxicity. No deaths occurred with either IFX or ADA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Complete accrual of the Scottish nationwide \u2018real-life\u2019 experience demonstrates moderate effectiveness of anti tumour necrosis factor agents in severe PIBD but duration of effect is limited; significant financial issues (drug cost\u2014need for dose escalation and\/or multiple biological usage) and safety issues exist.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2013-305812","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T04:04:54Z","timestamp":1423800294000},"page":"399-405","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Anti-TNF therapy for paediatric IBD: the Scottish national experience"],"prefix":"10.1136","volume":"100","author":[{"given":"F L","family":"Cameron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M L","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Basheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Jamison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"McGrogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W M","family":"Bisset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P M","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R K","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D C","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,2,12]]},"reference":[{"key":"key-10.1136\/archdischild-2013-305812-1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","article-title":"Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease","volume":"135","author":"Van Limbergen","year":"2008","journal-title":"Gastroenterology"},{"key":"key-10.1136\/archdischild-2013-305812-2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ibd.21797","article-title":"Rising incidence of pediatric inflammatory bowel disease in Scotland","volume":"18","author":"Henderson","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"key-10.1136\/archdischild-2013-305812-3","first-page":"995","article-title":"Presenting features of inflammatory bowel disease in Great Britain and Ireland","volume":"88","author":"Sawczenko","year":"2003","journal-title":"Br Med J"},{"key":"key-10.1136\/archdischild-2013-305812-4","unstructured":"Physicians RCo. Biological therapies audit sub group. National clinical audit report of biological therapies. Paediatric national report. UK IBD audit. London: Royal College of Physicians, 2013."},{"key":"key-10.1136\/archdischild-2013-305812-5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/MPG.0b013e31818aedb4","article-title":"Posterior reversible encephalopathy syndrome following infliximab infusion","volume":"48","author":"Zamvar","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key-10.1136\/archdischild-2013-305812-6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.crohns.2011.06.011","article-title":"A case of posterior reversible encephalopathy syndrome in a child with Crohn's disease treated with Infliximab","volume":"5","author":"Haddock","year":"2011","journal-title":"J Crohn's Colitis"},{"key":"key-10.1136\/archdischild-2013-305812-7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key-10.1136\/archdischild-2013-305812-8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/ibd.21871","article-title":"Antitumor necrosis factor treatment for pediatric inflammatory bowel disease","volume":"18","author":"de Bie","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key-10.1136\/archdischild-2013-305812-9","unstructured":"National Institute for Clinical E. Guidance on the use of infliximab for Crohn's disease. NICE 2002(1):40."},{"key":"key-10.1136\/archdischild-2013-305812-10","unstructured":"Nice. Infliximab (review) and adalimumab for the treatment of Crohn's disease. NICE technology appraisal guidance 187 2010."},{"key":"key-10.1136\/archdischild-2013-305812-11","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/MPG.0b013e3181c92caa","article-title":"Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease","volume":"50","author":"Wilson","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key-10.1136\/archdischild-2013-305812-12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"key-10.1136\/archdischild-2013-305812-13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate-to-severe ulcerative colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.1136\/archdischild-2013-305812-14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ibd.20788","article-title":"Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy","volume":"15","author":"Ruemmele","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"key-10.1136\/archdischild-2013-305812-15","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.1136\/archdischild-2013-305812-16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2013-305812-17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti\u2013tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I Trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"key-10.1136\/archdischild-2013-305812-18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"key-10.1136\/archdischild-2013-305812-19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"key-10.1136\/archdischild-2013-305812-20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"key-10.1136\/archdischild-2013-305812-21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.crohns.2012.03.016","article-title":"Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis","volume":"7","author":"McDermott","year":"2013","journal-title":"J Crohn's Colitis"},{"key":"key-10.1136\/archdischild-2013-305812-22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"key-10.1136\/archdischild-2013-305812-23","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2036.2011.04603.x","article-title":"A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease","volume":"33","author":"Russell","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"(Suppl A)","key":"key-10.1136\/archdischild-2013-305812-24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"key-10.1136\/archdischild-2013-305812-25","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1038\/ajg.2009.493","article-title":"Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease","volume":"104","author":"Rosh","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/archdischild-2013-305812-26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2036.2010.04507.x","article-title":"The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited","volume":"33","author":"De Bie","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/archdischild-2013-305812-27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00005176-199105000-00005","article-title":"Development and validation of a pediatric Crohn's disease activity index","volume":"12","author":"Hyams","year":"1991","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key-10.1136\/archdischild-2013-305812-28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"key":"key-10.1136\/archdischild-2013-305812-29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.mpg.0000189137.06151.33","article-title":"Infliximab dependency in a national cohort of children with Crohn's disease","volume":"42","author":"Wewer","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key-10.1136\/archdischild-2013-305812-30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MPG.0b013e31803e171c","article-title":"Infliximab use in children and adolescents with inflammatory bowel disease","volume":"45","author":"de Ridder","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key-10.1136\/archdischild-2013-305812-31","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/ibd.21615","article-title":"Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study","volume":"17","author":"Cromb\u00e9","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"key-10.1136\/archdischild-2013-305812-32","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/MIB.0000000000000083","article-title":"Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease","volume":"20","author":"Church","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key-10.1136\/archdischild-2013-305812-33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.crohns.2012.03.006","article-title":"Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease","volume":"7","author":"Assa","year":"2013","journal-title":"J Crohn's Colitis"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2013-305812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:37:14Z","timestamp":1601109434000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2013-305812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,12]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,3,17]]},"published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1136\/archdischild-2013-305812"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2013-305812","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,12]]}}}